Introduction
The human tumor suppressor gene BRCA2 encodes a large protein of 3418 amino acids. Mutations of BRCA2 contribute to a signi®cant portion of hereditary breast cancers. BRCA2 protein has no signi®cant homology with any protein of known function. The overall homology between human and mouse BRCA2 is moderate at about 59%. Highly conserved regions (475% homology) have been identi®ed in human and mouse BRCA2. It is expected that important functions of BRCA2 reside in these conserved domains. Based on the functional analysis of the conserved BRCA2 domains, several models have been proposed for the role of BRCA2 in tumor suppression.
An N-terminus conserved domain in exon 3 (amino acids 48 ± 105) has been implicated in transcriptional regulation of gene expression (Milner et al., 1997; Nordling et al., 1998) . Deletion of this region has been identi®ed in breast cancers (Nordling et al., 1998) . Therefore, the transcription activity itself is directly relevant to tumorigenesis.
Although the overall sequence in exon 11 shows only moderate homology between mouse and human BRCA2, eight internal BRC repeats in exon 11 are highly conserved (Bignell et al., 1997) . Each of the repeats is about 90 amino-acid long, and some of these repeats interact with RAD51 (Katagiri et al., 1998; Marmorstein et al., 1998; Wong et al., 1997) . A conserved C-terminal BRCA2 domain (amino acids 3196 ± 3232 of mouse BRCA2) also mediates BRCA2/ RAD51 interaction , and corresponds to a human BRCA2 C-terminus domain that is deleted in most truncating mutations of BRCA2. This region of mouse BRCA2 has 72% amino acid identity with human BRCA2. Functional analysis of these conserved domains in BRCA2 suggests that human BRCA2 may participate in RAD51-dependent DNA homologous recombination, thereby serving as a`caretaker' of genome stability. Mutation of BRCA2 that directly aects these RAD51-interaction domains could result in genomic instability, and promote tumorigenesis Yuan et al., 1999) .
A third model involves the cellular localization of BRCA2 proteins. The functional nuclear localization signals (NLS) for BRCA2 have been identi®ed near the C-terminus (Spain et al., 1999; Yano et al., 2000) . Most of the BRCA2 mutations identi®ed in breast cancers are truncations, resulting in deletion of the C-terminal NLS. It is possible that the lack of NLS in BRCA2 mutants results in abnormal cellular localization of BRCA2, preventing BRCA2 function (such as transcription and genome stability control), and subsequently responsible for tumorigenesis associated with BRCA2 mutation. This model may explain cases that involve the deletion of NLS in BRCA2 patients. However, some internal mutations, as exempli®ed by deletion of the transcriptional domain , would not aect the cellular location of BRCA2. They may still be responsible for tumorigenesis.
BRCA2 may be a protein with multiple functional domains. Another highly conserved region precedes the C-terminus RAD51-interaction domain. This domain is the longest conserved domain in BRCA2. It covers exons 14 ± 24 (Gayther and Ponder, 1998) . The role of this region in tumorigenesis is unclear. It is anticipated that this conserved domain carries essential, yet to be identi®ed, functions of BRCA2. It may possess cellular functions other than RAD51-associated DNA homologous recombination. Identi®-cation of novel proteins associating with BRCA2 would provide clues for additional BRCA2 functions. Using part of the long internal conserved domain covering exon 14 ± 24 as`bait' in a yeast two-hybrid screen, we identi®ed a novel nuclear protein, designated BCCIPa that interacts with a part of this conserved region.
Results and discussion

Identification of a BRCA2-interacting protein, BCCIPa
Amino acids 2883 ± 3053 of BRCA2 (termed BRCA2H) forms the longest internal conserved region encoded by exons 14 ± 24. BRCA2H is 78% identical between mouse and human, compared to the overall homology of 59%. Using Gal4-DB/BRCA2H as`bait' in a yeast two-hybrid assay, we screened 4610 5 independent clones of a human cDNA library, and identi®ed 14 interacting clones. DNA sequencing identi®ed ®ve clones that were derived from the same gene. Clone number 5 contained the longest cDNA, and encoded an open reading frame with a stop codon at the 3'-end, but no translation start codon at the 5'-end. This gene was assigned the symbol of BCCIP by the HUGO Gene Nomenclature Committee.
The sequence of our BCCIP cDNA was compared to databases of human EST. From the resulting analysis, we concluded that our clone was missing 42 nucleotides from the 5'-end. In addition, we discovered that some BCCIP cDNA have dierent 3'-end. The two types of cDNA encode protein of either 322 or 314 amino acids, and designated BCCIPa and BCCIPb. BCCIPa and BCCIPb have identical amino acids N-terminus 258 amino acids, but dier in their C-terminus ( Figure 1a) .
Further analysis showed that amino acids 45 ± 100 of BCCIP shares 29% identity and 58% similarity to the Ca-binding domain of M-calpain (Figure 1b ) (Pontremoli et al., 1999) . The same region also shares homology with the N-terminus Ca-binding site of calmodulin. Calmodulin is composed of three distinct domains (Yjandra et al., 1999) , an N-terminus calcium binding domain, a C-terminus calciumbinding domain, and an internal helix domain. In addition to the Ca-binding site, amino acids 100 ± 150 of human BCCIP also share homology with the internal helix of calmodulin. Amino acids 50 ± 150 of human BCCIP shares 26% identity and 45% similarity with amino acids 1 ± 90 of the calcium binding regulator protein calmodulin (Yjandra et al., 1999) (Figure 1b) . Therefore, BCCIP is a putative Ca-binding protein.
Finally, we identi®ed BCCIP-homologous genes from C. elegans, S. cerevisiae, and A. thaliana. Their anticipated protein sequences share a common structural pro®le with human BCCIPa and BCCIPb. All have an N-terminus acidic domain (NAD) rich in residues DE (aspartate and glutamate), an internal conserved domain (ICD), and a C-terminus variable domain (CVD) (Figure 2a) .
The DE-rich NAD domain shares moderate homology with many proteins having acidic domains. The CVD shares no homology among BCCIP family members, except that mouse BCCIP and human BCCIPb are *70% identical. The ICD is evolutionary conserved among the species analysed. For example, human and mouse BCCIP share 97% similarity, while the yeast and plant BCCIP share about 70% similarity to human BCCIP (Figure 2a ). The putative Ca-binding domain resides in the ICD (Figure 2b ).
In vivo interaction between BCCIPa and BRCA2
In order to con®rm the complex formation between BRCA2 and BCCIP in vivo, the proteins were expressed in 293 human kidney cells, and coimmunoprecipitation experiments were performed.
In the ®rst experiment, HA-tagged BRCA2 fragments BRCA2F (amino acids 2883 ± 3418) and BRCA2B (amino acids 2883 ± 3194) were co-expressed with Flag-tagged BCCIPa in 293 cells. The HA-tagged BRCA2 proteins were precipitated with an anti-HA anity matrix, and co-precipitated Flag-BCCIPa was detected by anti BCCIP antibodies. As demonstrated in Figure 3a , HA-tag alone (negative control) did not precipitate BCCIPa (Figure 3a , lane 4). However, BCCIPa was co-precipitated with both HA-BRCA2F and HA-BRCA2B (Figure 3a , lanes 5 and 6), suggesting that full-length BCCIPa interacts with the BRCA2.
In a second experiment, HA-tagged BCCIPa, UBC9, and RAD51 proteins were transiently expressed in 293 cells, and immunoprecipitated with the anti-HA anity matrix. The precipitated HA-tagged proteins were detected with anti-HA tag (lower panel of Figure 3b ). Co-immunoprecipitated endogenous BRCA2 proteins were detected by rabbit anti-BRCA2 antibodies (upper panel of Figure 3b ). As demonstrated in the top panel of Figure 3b (lane 8), endogenous BRCA2 protein was precipitated with HA-RAD51 as previously demonstrated (Marmorstein et al., 1998; Tan et al., 1999) , and HA-tag ( Figure 3b , top panel, lane 5) and HA-UBC9 ( Figure 3b , top panel, lane 7) did not precipitate BRCA2. However, HA-BCCIPa co-precipitated BRCA2. These data suggest a stable complex formation between full-length BRCA2 and BCCIPa in human cells.
A small region of BRCA2 is responsible for BCCIP interaction
To further characterize the interaction between BCCIPa and BRCA2, we fused a series of BRCA2 fragments with the Gal4-DNA binding domain, and tested their interaction with Gal4-DNA activation domain fused BCCIPa protein using LacZ as reporter in the independent yeast strain SF526. As shown in Figure  4a , BRCA2H undoubtedly interacts with BCCIP; the minimum interacting region of BRCA2 is in amino acids 2973 ± 3001.
To con®rm this, a set of GST-fusion proteins of BRCA2 fragments was puri®ed. GST-BRCA2 proteins were incubated with His-BCCIPa protein, and pulled down with glutathion beads. Bound HisBCCIPa proteins were analysed with Western blot. As shown in Figure 4b , GST protein and resin alone could not pull down His-BCCIPa. However, BRCA2
proteins containing region 2973 ± 3001 pulled down His-BCCIPa, suggesting an interaction between HisBCCIPa and this BRCA2 region. This region is 71% identical between mouse and human BRCA2, signi®cantly above the average homology between human and mouse BRCA2. Since puri®ed proteins were used for the binding assay, this demonstrates that BRCA2 and BCCIPa form a direct protein ± protein interaction.
Recombinant BCCIPa protein, BCCIP antibodies, and expression of BCCIP in human tissues
We subcloned the BCCIPa into pET28 and puri®ed His tagged BCCIP recombinant protein from bacteria ( Figure 5a , lane 2). GST tagged BCCIPa proteins were also puri®ed ( Figure 5a , lane 3). The His-BCCIPa was used to make rabbit polyclonal antibodies against BCCIP, and GST-BCCIPa was used to anity purify These antibodies are reactive to two species of proteins from human skin ®broblasts (HSF) and HT1080 ®brosarcoma cells (Figure 5b ). Since BCCIPa shares signi®cant homology to BCCIPb, and the antibodies recognize the N-terminus common region of BCCIPa and BCCIPb, we predict that the top band (*50 kDa) is BCCIPa (322 amino acids), and the lower band (*46 kDA) is BCCIPb (314 amino acids).
A human tissue protein membrane was purchased from DNA Technology Inc. Although the resolution of the pre-made membrane was compromised, and it is hard to distinguish the bands for BCCIPa and BCCIPb in tissues (Figure 5c ), it is interesting that the BCCIP proteins are highly expressed in testis, as are BRCA2 and RAD51 (Shinohara et al., 1993) .
Nuclear localization of BCCIP
To determine the cellular localization of BCCIP, we stained the breast cancer cell line MCF-7 with the anity puri®ed polyclonal BCCIP antibodies. As shown in Figure 6 , BCCIP proteins are predominantly expressed in the nucleus. Under the same condition, pre-immuno serum did not react with the nucleus (data not shown). It is interesting that BCCIP reactive proteins do not colocalize with condensed chromosome DNA during mitosis (Figure 6a,c) . Confocal microscopy of HeLa cells and human skin ®broblasts showed the same cellular distribution as MCF-7 cells (data not shown). We also expressed EGFP-tagged BCCIPa protein in HeLa cells, con®rming that the majority of the BCCIPa protein localizes to the nucleus (data not shown).
BCCIPa is located on chromosome 10 at q25.3 ± 26.2
We used BCCIPa cDNA as a probe for a FISH analysis. Among 100 mitotic cells analysed, 67 of them have paired FISH signals, and all of them were present near the end of chromosome 10q (Figure 7a ). Further analysis mapped this gene to 10q25.3 ± 26.2 ( Figure  7b ). To con®rm this ®nding, we used the BCCIP sequence as probe to search a human chromosome marker database, and identi®ed a marker (SGC33832) at chromosome 10q26.1. This marker has identical sequence to part of the BCCIPa cDNA. Therefore, this result con®rmed that BCCIPa is present at 10q25.3 ± 26.2, and is likely centered at 10q26.1.
Abnormalities in regions of chromosome 10q25.2 ± 26.2 have been observed in many tumors, including brain tumors (Maier et al., 1997; Rasheed et al., 1995) , endometrial tumors (Peier et al., 1995) , lung cancers (Kim et al., 1998; Petersen et al., 1998) , melanoma (Robertson et al., 1999; Walker et al., 1995) , and other tumors (Ittmann, 1996) . It has also been reported that the deletion of this region is responsible for develop- The double-band pattern is not readily visible in the tissues in this illustration due to the compromised resolution of the pre-made membrane provided by DNA Technology. However, the same double-band pattern, as in (b), was observed with a lighter exposure (data not shown) in all the tissues mental retardation in children (Tanabe et al., 1999; Taysi et al., 1982; Waggoner et al., 1999) .
At least one tumor suppressor is located in 10q25.3 ± 26.2 (Petersen et al., 1998; Rasheed and Bigner, 1991; Rasheed et al., 1995) . This tumor suppressor has been suggested to be responsible for brain tumors. A candidate tumor suppressor (DMBT1) was identi®ed in this region (Mollenhauer et al., 1997) . However, studies have shown that the status of DMBT1 in brain tumors has no connection with tumor phenotypes, suggesting that another gene in the region is responsible for brain tumors (Steck et al., 1999) .
Expression of BCCIP proteins in cancer cells
To evaluate a possible association of BCCIP with human cancers, we examined BCCIPa and BCCIPb expression in a number of cancer cell lines. As shown in Figure 8 , the expression level of BCCIPb is (Figure 8a ), A172 cells completely lack detectable BCCIPa expression, and U138MG and U118 showed reduced BCCIPa expression. Among the seven breast cancer cell lines (Figure 8b ), MCF-7, SK-BR-3, and HS578T showed reduced BCCIPa expression. In the four cases of endometrial tumor cells (Figure 8d ), two cell lines showed reduced BCCIPa levels, and two showed increased levels. However, the relative BCCIPa and BCCIPb expression level was relatively consistent among the seven tested lung cancer cell lines (Figure 8c ).
Inhibition of breast cancer cell growth by BCCIPa
We further expressed HA-tagged BCCIPa protein in a few brain and breast cancer cell lines. As demonstrated in Figure 9 , expression of HA-BCCIPa caused no signi®cant cell growth delay in normal human skin ®broblast (HSF) or in HT1080 ®bro-sarcoma cells. However, when the same control vector virus and HA-BCCIPa virus were used to infect brain and breast cancer cell lines, the HABCCIPa caused a growth delay. As shown by the growth curve of infected HSF, HT1080, A172, and MCF7 cells (Figure 10a ± d) , HA-BCCIPa inhibited the growth of MCF7 and A172, but not HSF and HT1080. As shown in Figure 10e , the levels of exogenously expressed HA-BCCIPa in MCF7, A172, HT1080 or HSF are comparable to the endogenous levels of BCCIP. These data conclude that expression of BCCIPa inhibits the growth of some breast cancer and brain tumor cells.
Considering the interaction of BCCIP with known tumor suppressor BRCA2, the similar tissue expression pattern of BCCIP with BRCA2, the BCCIP chromosome location to a region that is frequently altered in various tumors, the reduced or lacking of BCCIPa expression in tumor cells, and the inhibition of tumor cell growth, it is conceivable to suggest that BCCIP might be a candidate tumor suppressor for breast and brain tumors. However, more extensive studies are required to test this hypothesis. These will include at least, but not limited to, the following studies: extensive expression and mutation analysis of BCCIP in primary tumor specimens, suppression of tumor phenotypes in tumor cells by introducing wild type BCCIP into tumor cells with To summarize, we identi®ed a new protein, designed BCCIP that interacts with BRCA2. At least two isoforms of this protein are expressed in human tissues. BCCIP is evolutionarily conserved with several distinctive structural domains. A part of the internal conserved domain of BCCIP shares a moderate degree of homology with the a region of M-calpain and 
Materials and methods
Plasmids
A fragment of BRCA2 cDNA covering exons 21 ± 24 was isolated using RT ± PCR, and con®rmed by sequencing. This fragment was linked with BamHI and SalI sites, and fused to the Gal4-binding domain in the yeast two-hybrid vector pAS2-1, resulting in pAS2-1/BRCA2H. PCR primers tagged with BamHI/SalI sites were used to amplify regions of BRCA2 cDNA, and cloned into pGEX-5X (Pharmacia) to generate vectors that express glutathion S-transferase (GST) fused protein fragments of BRCA2. The same regions of BRCA2 were also cloned into the two-hybrid vector pGBT9, resulting pGBT9/BRCA2H, to express Gal4-DNA binding domain fused protein in yeast. BCCIPa cDNA was cloned into pET28 (Novagen), creating pET28/BCCIPa, which expresses histidine tagged BCCIPa protein in BL21 (DE3) cells. BCCIP cDNA was also cloned into pGEX-5x to generate pGEX/BCCIP, which expresses recombinant GST-BCCIP fusion protein in BL21 cells. All plasmid constructs were con®rmed by DNA sequencing. Plasmids that express HA-UBC9 and HA-RAD51 are described as before (Li et al., 2000) .
Recombinant proteins and BCCIP antibodies
Recombinant protein expression and puri®cation were performed as previously described (Shen et al., 1996b) . Brie¯y, pET28/BCCIPa was transfected into BL21(DE3) cells, and the (His) 6 -tagged BCCIP protein (His-BCCIPa) was expressed and puri®ed. GST-BCCIPa and GST-BRCA2 fusion proteins were expressed and puri®ed in BL21 cells using pGEX/BCCIPa, and pGEX/BRCA2 vectors. HisBCCIPa was injected into rabbits to produce polyclonal antibodies, and GST-BCCIPa was used for anity puri®ca-tion of polyclonal anti-BCCIP antibodies.
BCCIPa DNA sequence and human EST database analysis
Plasmids from positive clones of the two-hybrid screen were sequenced and data were analysed with DNA Star sequence analysis software. The GenBank nucleic acid and human EST databases were searched to identify matching ESTs. The complete cDNA sequence of BCCIPa was constructed from the cDNA sequence of our clones and matching ESTs.
Protein interaction assays
pAS2-1/BRCA2H was used to screen a cDNA library expressing Gal4-DNA activation domain fused proteins (Clonetech, Palo Alto, CA, USA) as described (Shen et al., 1996a) . MV103 cells hosting LacZ and Uracil, and Histidine reporters were used for the screen (Vidal, 1997) . To con®rm the two-hybrid interaction, an independent two-hybrid assay and in vitro GST pull-down assays were performed as described (Shen et al., 1996b) . Brie¯y, various regions of BRCA2 cDNA were cloned into pGBT9. These vectors were co-transfected with pACT/BCCIPa, and assayed for LacZ activity in the host cell strain SFY526 (Clontech, Palo Alto, CA, USA). GST-tagged BRCA2 fragments were bound to glutathione beads and incubated with His-tagged BCCIP protein. After extensive washing, His-BCCIPa proteins bound to GST-fusion proteins were analysed by Western blot using anti-BCCIP antibodies.
Immunoprecipitation and immunoblotting
Cultured human cells were collected, treated with lysis buer (150 mM NaCl, 1 mM EDTA, 50 mM Tris Cl, pH 7.5, 1% NP-40) for 30 min in ice, and sonicated, resulting in wholecell extract. One mg of whole-cell extract was incubated with 50 ml of anti-HA Anity Matrix (Roche Molecular Biochemicals) at 48C on a rocker for 2 h. The matrix was washed six times in 1 ml of cold lysis buer. Proteins bound to the beads were eluted in 26SDS sample buer by boiling for 5 min, then resolved by SDS ± PAGE and transferred to PVDF membrane (Osmonics). Immunoblotting using appropriate antibodies was as described before (Li et al., 2000) . To detect BRCA2, a rabbit anti-BRCA2 antibody (Oncogene Researcher Products) was used.
Immunostaining and confocal microscopy
Cells were cultured on a cover slip, and ®xed with cold 3% paraformaldehyde solution buered with PBS for 1 h. Fixed slides were treated with permeabilization buer (0.5% Triton X-100, 50 mM NaCl, 3 mM MgCl 2 , 300 mM sucrose, and 20 mM HEPES, pH 7.4) for 20 min. Slides were blocked with 2% BSA in PBS for 30 min at room temperature, and incubated with 1 mg/ml of primary anti-BCCIP antibodies overnight at 48C. After the primary antibody incubation, the slides were washed ®ve times with PBS, and incubated with rhodamin-conjugated anti-rabbit IgG antibodies (Pierce) for 30 min at room temperature. Slides were washed with PBS ®ve times, and mounted with Vectashield mounting solution containing 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA, USA). The slides were stored in the dark at 48C. A Zeiss LSM510 confocal microscope with Ar/Kr and UV laser sources was used to observe the stained slides, and images of the cells were digitally recorded.
Retroviral vectors
The neomycin selection marker in pLXSN (Clontech) was replaced by a puromycin gene to produce a pLXSP vector bearing the puromycin selection marker. An HA-tagged BCCIPa cDNA was cloned into the EcoRI/XhoI site of the pLXSP. This vector was used to produce replication de®cient virus in a package cell as described (Pear et al., 1997) . Target cells were infected two times a day for 2 days. Thirty-six hours after the last infection, cells were treated with 1 mg/ml of puromycin for 48 h. The puromycin-resistant cells were changed to fresh medium and incubated for an additional 3 days and counted, or replated for growth curve determinations.
Other procedures
Western blots were performed as described previously (Li et al., 2000) . Fluorescent in situ hybridization (FISH) was performed as described before (Shen et al., 1996a) using BCCIP cDNA as the probe. Tumor cell lines were purchased from ATCC.
Abbreviations GST, glutathion S-transferase; BCCIP, Brca2, Ca and Cip1 interacting protein; DAPI, 4', 6-diamidino-2-phenylindole; NAD, N-terminus acidic domain; ICD: internal conserved BRCA2/BCCIPa interaction and tumor inhibition J Liu et al domain; CVD, C-terminus variable domain; HSF, human skin ®broblast; FISH,¯uorescent in situ hybridization.
